Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

B10 L-BPA · B10

Small molecule · developed by Merck Sharp & Dohme LLC

Phase 2 Most advanced trial
2 Registered trials

What is B10 L-BPA?

B10 L-BPA is a boron-containing compound, a boronophenylalanine in which 10B replaces a position on L-phenylalanine, administered as an injection. It is used in boron neutron capture therapy (BNCT), in which neutron irradiation follows administration. It is studied in head and neck cancer and malignant brain tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
B10
Drug type
Small molecule
Therapy area
Oncology
Developer
Merck Sharp & Dohme LLC
In trials of
HRTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07003139 Phase 1/2 Malignant Brain Tumors Recruiting HRTX
NCT06952868 Phase 2 Head and Neck Cancer Recruiting HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Boron Neutron Capture TherapyHead and Neck CancerMalignant Brain Tumors

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.